Mobic May Gain Momentum After Bextra Withdrawal
Executive Summary
Boehringer Ingelheim's non-steroidal anti-inflammatory drug Mobic may be poised to emerge as a blockbuster product following the market withdrawal of Pfizer's COX-2 inhibitor Bextra
You may also be interested in...
Prexige Still Postponed: Novartis To Resubmit COX-2 Inhibitor In U.S. In 2007
Novartis plans to resubmit Prexige (lumiracoxib) in the U.S. in the first half of 2007; approval of the oral COX-2 inhibitor in the European Union and Canada for treatment of osteoarthritis symptoms was announced Nov. 7
Prexige Still Postponed: Novartis To Resubmit COX-2 Inhibitor In U.S. In 2007
Novartis plans to resubmit Prexige (lumiracoxib) in the U.S. in the first half of 2007; approval of the oral COX-2 inhibitor in the European Union and Canada for treatment of osteoarthritis symptoms was announced Nov. 7
Merck May Need New Arcoxia Trial Design Prior To FDA Approval
Merck may need to conduct additional Arcoxia clinical trials to gain FDA approval after the agency and its COX-2 inhibitor advisory committee cited flaws in the existing program